FinancingTacalyx’ extends seed capital financingLatest NewsGlycan target specialist Tacalyx GmbH expands its seed financing to €14m to advance its anti-TACA cancer therapies. Read more 11 June 2024 https://european-biotechnology.com/wp-content/uploads/2024/06/Peter_Sondermann__c__Tacalyx.jpg 800 1200 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2024-06-11 14:41:412024-06-20 16:23:32Tacalyx’ extends seed capital financing